Abstracts tagged "Kidney"

Abstract Number: 1768 • 2015 ACR/ARHP Annual Meeting
Improved Tissue Clearing and 2-Photon Imaging of Mouse Kidneys Reveals Immune Cell Architecture in Nephrotoxic Nephritis
Matthew Cheung, Dongyue Huang and Alfred Kim, Rheumatology, Washington University School of Medicine, Saint Louis, MO
Background/Purpose: Tissue clearing approaches such as CLARITY renders tissue transparent, and in combination with two-photon microscopy, enables microscopic visualization deep internal structures within unaltered organs.…
Abstract Number: 1850 • 2015 ACR/ARHP Annual Meeting
Increased Levels of Immunoglobulin Binding Protein 1 Are Associated with Disease Activity Including Renal Damage in Patients with Systemic Lupus Erythematosus
Eun-Ju Lee^1,2, Seokchan Hong³, Doo-Ho Lim¹, Yong-Gil Kim¹, Chang-Keun Lee¹ and Bin Yoo¹, ¹Division of Rheumatology, Department of Internal Medicine, Department of Rheumatology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, South Korea, ²Asan Institute for Life Science, Asan Medical Center, Seoul, South Korea, ³Department of Rheumatology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, South Korea
Background/Purpose: Systemic lupus erythematous (SLE) is a multisystem autoimmune inflammatory disease. Lupus nephritis (LN) is one of the most serious complications in patients with SLE.…
Abstract Number: 1911 • 2015 ACR/ARHP Annual Meeting
Monocyte Chemoattractant Protein-1 (MCP-1, CCL2) Is a Potential Local Marker of Renal Involvement in Scleroderma
Edward Stern^1,2, Cassandra Hong², Voon H. Ong², Aine Burns¹, Robert Unwin³ and Christopher P. Denton⁴, ¹Nephrology, Royal Free Hospital, London, United Kingdom, ²Rheumatology, UCL Division of Medicine, London, United Kingdom, ³Nephrology, UCL Division of Medicine, London, United Kingdom, ⁴Rheumatology and Connective Tissue Diseases, University College London, London, United Kingdom
Background/Purpose: Renal disease in scleroderma (SSc), including scleroderma renal crisis (SRC), remains a major clinical challenge. Previous studies showed up to 50% of SSc patients…
Abstract Number: 2016 • 2015 ACR/ARHP Annual Meeting
Functional Tertiary Lymphoid Structures within the Kidneys of Lupus Prone Mice Resembles Lymph Nodes in Gene Expression Profiling Analysis and Are Detected By in Vivo Imaging
Premasany Kanapathippillai, Sayed Esmaeil Dorraji and Kristin A Fenton, RNA and Molecular Pathology, UIT, The Artic University of Norway, Tromso, Norway
Background/Purpose: The formation of tertiary lymphoid structures (TLS) are known to occur during the development of several diseases, including systemic lupus erythematosus (SLE), but in…
Abstract Number: 2191 • 2015 ACR/ARHP Annual Meeting
Increased Risk of Acute and Chronic Renal Lesions Associated with Antiphospholipid Antibodies in Patients with Systemic Lupus Erythematosus: A Systematic Review and Meta-Analysis
Vinicius Domingues¹, DENIS WAHL² and Stephane Zuily³, ¹Rheumatology, New York University School Of Medicine, New York, NY, ²CHU de Nancy, Vascular Medicine Division and Regional Competence Centre For Rare Vascular And Systemic Autoimmune Diseases; and UMR_S U1116 Research Unit, Nancy, France, ³CHU de Nancy, Vascular Medicine Division and Regional Competence Centre For Rare Vascular And Systemic Autoimmune Diseases; and UMR_S U1116 Research Unit, France, Nancy, France
Background/Purpose : Renal lesions have been described in patients with antiphospholipid antibodies (aPL), however their associations with aPL are inconsistent among studies. Therefore our objective…
Abstract Number: 2349 • 2015 ACR/ARHP Annual Meeting
The Efficacy and Tolerability of Febuxostat in Hyperuricemic Patients with Severe Renal Impairment
Ji Seon Oh and Seungwon Choi, Division of Rheumatology, Department of Internal Medicine, University of Ulsan College of Medicine, Ulsan University Hospital, Ulsan, South Korea
Background/Purpose: Febuxostat has shown to be effective and safe in the treatment of hyperuricemia in patients with mild-to-moderate renal impairment without dose adjustment. However, there…
Abstract Number: 2350 • 2015 ACR/ARHP Annual Meeting
Efficacy and Safety of Febuxostat in 55 Gouty Patients with Stage 4/5 Chronic Kidney Disease: Results from a Retrospective Multicenter Study
Pierre-Antoine Juge¹, Marie-Elise Truchetet², Sébastien Ottaviani³, Cécile Vigneau⁴, Clotilde Loustau⁵, Divi Cornec⁶, Tristan Pascart⁷, Emilie Cornec-Legall⁸, Marine Florien⁹, Florian Bailly¹⁰, Thierry Schaeverbeke⁵, Alain Saraux¹¹, Philippe Dieude¹², Rene-Marc Flipo¹³, Georges Jean-Baptiste¹⁴, Pascal Richette¹⁵, Frederic Lioté¹⁶, Thomas Bardin^17,18, Gerard H. Chales¹⁹ and Hang-Korng Ea²⁰, ¹Rheumatology Department, Centre de Viggo Petersen, Lariboisère Hospital, Paris, France, ²Rheumatology, Pellegrin Hospital, Bordeaux, France, ³Hopital Lariboisière, Paris, France, ⁴Nephrology, Rennes University Hospital, Rennes, France, ⁵Rheumatology Department, Bordeaux Hospital, Bordeaux, France, ⁶Department of rheumatology, Brest Occidentale University, Brest, France, ⁷Rheumatology, Saint-Philibert Hospital, Lille, France, ⁸Nephrology Departement, Brest Hospital, Brest, France, ⁹Rheumatology Department, Pierre-Zobda-Quitman La Meynard, Fort-de-France, France, ¹⁰Rheumatology Department, La Pitié-Salpétrière Hospital, Paris, France, ¹¹Rheumatology Department, CHU de la Cavale Blanche, Brest Cedex, France, ¹²Rheumatology, Bichat Claude-bernard, Universitary Hospital, APHP, Paris, France, ¹³Rheumatology, University Hospital, Lille, France, ¹⁴Rheumatology and Internal Medicine, Zobda Quitman Hospital, Fort-de-France, Martinique, ¹⁵Université Paris Diderot, UFR médicale, Paris, France; APHP Hôpital Lariboisière, Fédération de Rhumatologie and Inserm U1132, Hôpital Lariboisière, Paris, France, ¹⁶Rheumatology Department; Inserm UMR-S606; Paris-Diderot University, hôpital Lariboisiere, Paris, France, ¹⁷Service de Rhumatologie, Hôpital Lariboisière, Paris, France, ¹⁸Rhumatology Departement, Hôpital Lariboisière, Paris, France, ¹⁹CHU RENNES, Rennes, France, ²⁰INSERM UMR1132, Paris Diderot University, Paris, France
Background/Purpose: Although allopurinol is the first urate lowering therapy (ULT), its limited dosage in gouty patients with stage 4 or 5 chronic kidney disease (CKD…
Abstract Number: 2356 • 2015 ACR/ARHP Annual Meeting
Major Cardiovascular Events in Gout Patients with Cardiovascular Disease or Heart Failure and Chronic Kidney Disease Initiating on Allopurinol or Febuxostat (Uloric)
JoAnne Foody¹, Robin Turpin², Beni Tidwell³ and Kathy Schulman⁴, ¹Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ²Medical Affairs, Takeda Pharmaceuticals International, Deerfield, IL, ³ORS, Shrewsbury, MA, ⁴Outcomes Research Solutions, Inc., Waltham, MA
Background/Purpose: Xanthine oxidase inhibitors (XOI) reduce both urate levels and oxidative stress in the vasculature, both of which are cardiovascular disease (CVD) risk factors. However,…
Abstract Number: 2911 • 2015 ACR/ARHP Annual Meeting
Tubulointerstitial Involvement in Lupus Nephritis
Angela Pakozdi¹, Ravindra Rajakariar², Michael Sheaff³ and Dev Pyne¹, ¹Rheumatology, Barts Health NHS Trust, London, United Kingdom, ²Renal Medicine, Barts Health NHS Trust, London, United Kingdom, ³Histopathology, Barts Health NHS Trust, London, United Kingdom
Background/Purpose: Tubulointerstitial disease is frequent in lupus nephritis (LN) with immune deposits being present in up to one third of patients.[1,2] Lesions including interstitial infiltration,…
Abstract Number: 2912 • 2015 ACR/ARHP Annual Meeting
Concomitant Kidney Disease in Patients with Lupus Nephritis
Paul Hoover¹, Jose A. Gomez Puerta², Alexander Fine¹, Helmut Rennke³ and Karen H. Costenbader⁴, ¹Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, ²Grupo de Inmunología e Inmunogenética, GICIG, Universidad de Antioquia, Medellín, Colombia, Medellín, Colombia, ³Pathology, Brigham and Women's Hospital, Boston, MA, ⁴Rheumatology, Immunology & Allergy, Brigham and Women's Hospital, Boston, MA
Background/Purpose: The most common and clinically and histologically best-characterized SLE kidney disease is lupus nephritis (LN). However, other forms of kidney disease can and do…
Abstract Number: 2917 • 2015 ACR/ARHP Annual Meeting
Combined Proliferative and Membranous Lupus Nephritis: Is the Prognosis Really Poor?
Ryota Sakai¹, Akiko Shibata¹, Kentaro Chino¹, Jun Kikuchi², Tsuneo Kondo¹, Ayumi Okuyama¹, Hirofumi Takei¹ and Koichi Amano¹, ¹Department of Rheumatology and Clinical Immunology, Saitama Medical Center, Saitama Medical University, Saitama, Japan, ²Rheumatology and Clinical Immunology, Saitama Medical Center, Saitama Medical University, Saitama, Japan
Background/Purpose: Using light microscopy (LM) or immunofluorescence (IF), combined proliferative and membranous lupus nephritis (LN) is defined as an active proliferative class III/IV lesion and…
Abstract Number: 58 • 2015 ACR/ARHP Annual Meeting
Attribution of Cause of End-Stage Renal Disease Among Systemic Lupus Erythematosus Patients
Laura Plantinga¹, Cristina Drenkard¹, Stephen Pastan² and S. Sam Lim³, ¹Department of Medicine, Emory University, Atlanta, GA, ²Department of Medicine, Division of Renal Medicine, Emory University, Atlanta, GA, ³Emory University School of Medicine, Atlanta, GA
Background/Purpose: The attributed cause of end-stage renal disease (ESRD) in the United States Renal Data System (USRDS) is often used to identify systemic lupus erythematosus…
Abstract Number: 606 • 2015 ACR/ARHP Annual Meeting
Impaired Kidney Function Improves Treatment Response after 6 Months of Methotrexat Treatment in Rheumatoid Arthritis Patients
Paul Studenic¹, Farideh Alasti¹, Josef S. Smolen^2,3, Helmuth Haslacher⁴ and Daniel Aletaha⁵, ¹Department of Internal Medicine 3, Division of Rheumatology, Medical University Vienna, Vienna, Austria, ²Department of Medicine 3, Division of Rheumatology, Medical University Vienna, Vienna, Austria, ³2nd Department of Medicine, Hietzing Hospital, Vienna, Austria, ⁴Laboratory Medicine, Medical University Vienna, Vienna, Austria, ⁵Department of Internal Medicine III; Division of Rheumatology, Medical University Vienna, Vienna, Austria
Background/Purpose: Methotrexate (MTX) and leflunomide are categorized as DMARDs of first choice in treating rheumatoid arthritis patients. MTX should be used cautiously in patients with…
Abstract Number: 991 • 2015 ACR/ARHP Annual Meeting
CaMK4 Facilitates Recruitment of IL-17 Producing Cells to Target Organs through the CCR6/CCL20 Axis in Th17-Driven Inflammatory Diseases
Tomohiro Koga^1,2, Kotaro Otomo³, Masayuki Mizui², Nobuya Yoshida⁴, José C. Crispin², Atsushi Kawakami⁵ and George C. Tsokos⁴, ¹Department of Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, ²Medicine/Rheumatology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, ³Rheumatology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, ⁴Division of Rheumatology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, ⁵Department of Immunology and Rheumatology, Nagasaki University, Nagasaki, Japan
Background/Purpose: The recruitment of IL-17 producing T helper (Th17) cells to the inflammatory sites has been implicated in the development of organ damage in inflammatory…
Abstract Number: 1767 • 2015 ACR/ARHP Annual Meeting
Noninvasive Assessment of Macrophage Activation in Experimental Glomerulonephritis Using Optical Imaging with Near-Infrared Light Serves As a Surrogate of Disease Activity
Sebastian Braehler¹, Dongyue Huang², Matthew Cheung², Walter Akers³ and Alfred Kim², ¹Pathology & Immunology, Washington University School of Medicine, Saint Louis, MO, ²Rheumatology, Washington University School of Medicine, Saint Louis, MO, ³Mallinckrodt Institute of Radiology, Washington University School of Medicine, Saint Louis, MO
Background/Purpose: Glomerulonephritis (GN) represents a major cause of morbidity & mortality. The standard for diagnosing GN is through renal biopsy, but this is not performed…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].